Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	1,114,298	268,771	1,708,857	976,525
Depreciation	206	347	620	1,041
Research and development (including stock-based compensation (Note 7))	332,208	135,057	578,581	372,836
Total operating expenses	1,446,712	404,175	2,288,058	1,350,402
Loss from operations	(1,446,712)	(404,175)	(2,288,058)	(1,350,402)
Other (income) expense:
Forgiveness of debt	(34,800)		(34,800)
Interest expense	137,911	103,084	545,422	363,424
Total other expense	103,111	103,084	510,622	363,424
Net loss	(1,549,823)	(507,259)	(2,798,680)	(1,713,826)
Net loss attributable to the noncontrolling interest	1,219	516	2,258	1,789
Net loss applicable to Bion's common stockholders	$ (1,548,604)	$ (506,743)	$ (2,796,422)	$ (1,712,037)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.05)	$ (0.02)	$ (0.09)	$ (0.06)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	32,919,811	29,640,938	31,624,309	28,633,602